Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Pharmacology|October 22, 2009
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smokingYuyan Jin, Bruce G Pollock, Kim Coley, et al.
Biological Psychiatry|June 14, 2002
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidoneMichael F Green, Stephen R Marder, Shirley M Glynn, et al.
Schizophrenia Bulletin|June 6, 2002
The Mount Sinai conference on the pharmacotherapy of schizophreniaStephen R Marder, Susan M Essock, Alexander L Miller, et al.
Psychological Medicine|May 30, 2020
Motivational and cognitive factors linked to community integration in homeless veterans: Study 2 - clinically diverse sampleJonathan K Wynn, Sonya Gabrielian, Gerhard Hellemann, et al.
The Journal of Clinical Psychiatry|February 5, 2009
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studiesPhilip G Janicak, Ira D Glick, Stephen R Marder, et al.
Psychiatry Research|June 16, 2018
Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-upAnn Faerden, Siv Hege Lyngstad, Carmen Simonsen, et al.
Schizophrenia Bulletin|March 3, 2010
Report from the working group conference on multisite trial design for cognitive remediation in schizophreniaRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
Schizophrenia Bulletin Open|November 6, 2024
Rationale and Challenges for a New Instrument for Remote Measurement of Negative SymptomsDavid Gordon Daniel, Alex S Cohen, Philip D Harvey, et al.
The American Journal of Psychiatry|August 6, 2003
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomesStephen R Marder, Shirley M Glynn, William C Wirshing, et al.
The American Journal of Psychiatry|September 28, 2007
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairmentsRobert W Buchanan, Daniel C Javitt, Stephen R Marder, et al.
Pageof 17